Clinical Trials
5 trialsNCT03804996 2024-04-08
Study of TG-1801 in Subjects With B-Cell Lymphoma
TG Therapeutics, Inc.
Phase 1 Completed
NCT02535286 2022-10-20
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
TG Therapeutics, Inc.
Phase 1 Completed
NCT02006485 2019-11-05
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
TG Therapeutics, Inc.
Phase 1 Completed
NCT02276963 2019-06-06
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Johns Hopkins University
Phase 1 Completed
NCT01098188 2012-04-30
LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia
Laboratoire français de Fractionnement et de Biotechnologies
Phase 1 Completed